{"id": "1353462766443487232", "creation": 1611525644.0, "user_id": "1249224696937103368", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 1, "reply_count": 0, "like_count": 0, "quote_count": 0}}, "text": "Phase 1-2a trial interim results of the candidate #vaccine Ad26.COV2.S (Johnson &amp; Johnson and DHHS) for #COVID19 indicate acceptable safety &amp; reactogenicity profile after single vaccination with high or low dose schedule. #SciComm #RxTwitter #MedTwitter https://t.co/E1HMqaQ5pp", "first_save": 1634559108.199414, "hashtags": ["#VACCINE", "#COVID19", "#SCICOMM", "#RXTWITTER", "#MEDTWITTER"]}